AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Blueprint Medicines Corp (NASDAQ:BPMC)
127.905 USD
+0.005 0.004%Sponsored Reports
Loading...
| Previous Close (in USD) | 127.9 |
|---|---|
| Change | +0.005 0.004% |
| 52 W H/L (in USD) | 121.900/72.240 |
| EBITDA (in USD) | -262.129M |
| PE Ratio | -- |
| Volume | 1883428 |
| Diluted Eps TTM | -2.09 |
| Total Assets (in USD) | 1049.25M |
|---|---|
| Total Liabilities (in USD) | 918.641M |
| Revenue TTM (in USD) | 434.415M |
| Cash (in USD) | 71.286M |
| Market Cap (in USD) | 6,007.635 M |
| Revenue Per Share TTM | 6.986 |
| Gross Profit TTM (in USD) | 177.275M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
45 Sidney Street, Cambridge, MA, United States, 02139
617 374 7580
Employees: 638
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Jeffrey W. Albers J.D., M.B.A., MBA | Exec. Chairman | 1971 |
| 2. | Ms. Kathryn Haviland | Pres, CEO & Director | 1976 |
| 3. | Mr. Alexis A. Borisy A.M. | Co-Founder & Director | 1972 |
| 4. | Mr. Michael Landsittel | Chief Financial Officer | 1972 |
| 5. | Dr. Percy H. Carter M.B.A., Ph.D. | Chief Scientific Officer | 1971 |
| 6. | Dr. Fouad Namouni M.D. | Pres of R&D | 1969 |
| 7. | Ms. Christina Rossi | Chief Operating Officer | 1976 |
| 8. | Dr. Christopher K. Murray | Sr. VP of Technical Operations | 1963 |
| 9. | Jenna Cohen | Sr. Director & Head of Investor Relations | NA |
| 10. | Ms. Tracey L. McCain Esq. | Exec. VP, Chief Legal & Compliance Officer and Sec. | 1968 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.930 2.657% | 74.15 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.352 0.482% | 72.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+4.320 0.973% | 443.83 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+12.300 2.546% | 485.54 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -552.281M | -641.084M | 314.94M | -347.694M | -236.642M |
| Minority Interest | - | - | - | - | - |
| Net Income | -557.517M | -644.085M | 313.882M | -328.703M | -236.642M |
| Selling General Administrative | 237.374M | 195.293M | 157.743M | 96.388M | 47.928M |
| Gross Profit | 186.223M | 162.146M | 793.31M | 66.512M | 44.521M |
| Reconciled Depreciation | 11.735M | 6.479M | 6.559M | 5.259M | 4.246M |
| Ebit | -549.253M | -648.46M | 302.148M | -366.585M | -240.815M |
| Ebitda | -537.518M | -641.981M | 308.707M | -361.326M | -236.569M |
| Depreciation And Amortization | 11.735M | 6.479M | 6.559M | 5.259M | 4.246M |
| Operating Income | -549.253M | -648.46M | 302.148M | -366.585M | -247.028M |
| Other Operating Expenses | 741.554M | 822.061M | 485.028M | 427.838M | 291.549M |
| Interest Expense | 16.767M | 7.376M | 12.792M | 13.732M | 0.073M |
| Tax Provision | 5.236M | 3.001M | 1.058M | - | - |
| Interest Income | - | - | - | 13.732M | 0.073M |
| Net Interest Income | -16.767M | 2.386M | 6.599M | 13.732M | -0.073M |
| Income Tax Expense | 5.236M | 3.001M | 1.058M | -18.991M | 10.459M |
| Total Revenue | 204.036M | 180.08M | 793.735M | 66.512M | 44.521M |
| Total Operating Expenses | 723.741M | 804.127M | 484.603M | 427.838M | 291.549M |
| Cost Of Revenue | 17.813M | 17.934M | 0.425M | 331.45M | 243.621M |
| Total Other Income Expense Net | -3.028M | 7.376M | 12.792M | 18.891M | 10.459M |
| Net Income From Continuing Ops | -557.517M | -644.085M | 313.882M | -414.206M | -281.163M |
| Net Income Applicable To Common Shares | -557.517M | -644.085M | 313.882M | -347.694M | -236.642M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 1049.25M | 1349.902M | 1252.225M | 1718.393M | 707.694M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 33.351M | 35.024M | -539.465M | -655.853M | 379.436M |
| Total Liab | 918.641M | 835.225M | 281.49M | 248.305M | 243.335M |
| Total Stockholder Equity | 130.609M | 514.677M | 970.735M | 1470.088M | 464.359M |
| Other Current Liab | 127.992M | -295.546M | 96.763M | 105.938M | 88.706M |
| Common Stock | 0.061M | 0.06M | 0.059M | 0.058M | 0.049M |
| Capital Stock | 0.061M | 0.06M | 0.059M | 0.058M | 0.049M |
| Retained Earnings | -2339.942M | -1832.958M | -1275.441M | -631.356M | -945.238M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 26.784M | 19.809M | 569.292M | 15.388M |
| Cash | 71.286M | 119.709M | 209.948M | 684.636M | 113.938M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 214.923M | 183.234M | 149.765M | 130.802M | 106.482M |
| Current Deferred Revenue | 0.812M | 448.621M | 36.576M | 12.559M | 6.16M |
| Net Debt | 702.836M | 122.742M | -98.54M | -595.032M | -17.989M |
| Short Term Debt | 81.409M | 27.43M | 8.093M | 7.935M | 6.823M |
| Short Long Term Debt | 30.278M | 16.851M | - | - | - |
| Short Long Term Debt Total | 774.122M | 242.451M | 111.408M | 89.604M | 95.949M |
| Other Stockholder Equity | 2473.985M | 2358.018M | 2250.25M | 2106.6M | 1412.083M |
| Property Plant Equipment | - | 33.344M | 30.7M | 34.129M | 38.361M |
| Total Current Assets | 808.393M | 1046.651M | 554.025M | 927.759M | 516.786M |
| Long Term Investments | 84.319M | 133.48M | 557.529M | 677.873M | 64.406M |
| Short Term Investments | 639.355M | 825.283M | 267.166M | 187.213M | 369.616M |
| Net Receivables | 43.178M | 36.938M | 37.03M | 25.309M | 23.412M |
| Long Term Debt | 208.535M | 535.277M | - | - | - |
| Inventory | 21.223M | 29.697M | 21.817M | 8.581M | -434.022M |
| Accounts Payable | 4.71M | 2.729M | 8.333M | 4.37M | 4.793M |
| Accumulated Other Comprehensive Income | -3.495M | -10.443M | -4.133M | -5.214M | -2.535M |
| Non Currrent Assets Other | 30.65M | 26.784M | 19.809M | 11.093M | 15.388M |
| Non Current Assets Total | 240.857M | 303.251M | 698.2M | 790.634M | 190.908M |
| Capital Lease Obligations | 93.684M | 103.368M | 111.408M | 89.604M | 95.949M |
| Long Term Debt Total | - | 535.277M | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -140.332M | 35.381M | -431.09M | -2.453M | -148.411M |
| Total Cashflows From Investing Activities | -149.541M | -225.86M | -434.249M | -16.466M | -161.088M |
| Total Cash From Financing Activities | 561.81M | 50.716M | 617.759M | 340.638M | 4.454M |
| Net Income | -557.517M | -644.085M | 313.882M | -347.694M | -236.642M |
| Change In Cash | -90.215M | -474.685M | 570.2M | 46.175M | -331.643M |
| Begin Period Cash Flow | 215.119M | 689.804M | 119.604M | 73.429M | 405.072M |
| End Period Cash Flow | 124.904M | 215.119M | 689.804M | 119.604M | 73.429M |
| Total Cash From Operating Activities | -502.277M | -298.653M | 387.035M | -278.015M | -175.009M |
| Depreciation | 11.735M | 6.479M | 6.559M | 5.259M | 4.246M |
| Other Cashflows From Investing Activities | -0.29M | -258.152M | -258.152M | -2.453M | -148.411M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -8.922M | -12.561M | -6.707M | 8.97M | -6.707M |
| Sale Purchase Of Stock | - | - | 79.305M | 340.754M | 6.144M |
| Other Cashflows From Financing Activities | 561.81M | 50.716M | 35.265M | -0.4M | -0.281M |
| Capital Expenditures | 8.919M | 261.241M | 3.159M | 14.013M | 12.677M |
| Change In Working Capital | -53.769M | -23.68M | -15.618M | 9.725M | 31.24M |
| Other Non Cash Items | -1.697M | 269.642M | 6.22M | 4.991M | -4.387M |
| Free Cash Flow | -511.196M | -559.894M | 383.876M | -292.028M | -187.686M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 945651 |
| 2. | Delaware Small Cap Core I | 7 months ago | 908168 |
| 3. | Vanguard Small Cap Growth Index Inv | 7 months ago | 873376 |
| 4. | Vanguard Explorer Inv | 8 months ago | 788840 |
| 5. | Fidelity Small Cap Index | 8 months ago | 638963 |
| 6. | Pictet Biotech | 1 year ago | 624039 |
| 7. | iShares Russell 2000 Growth ETF | 6 months ago | 568418 |
| 8. | Fidelity Select Biotechnology | 7 months ago | 542652 |
| 9. | Lord Abbett Growth Leaders I | 8 months ago | 523548 |
| 10. | Lord Abbett & Co. Growth Equity- SA | 8 months ago | 523548 |
| 11. | Polar Capital Biotech S Inc | 7 months ago | 515000 |
| 12. | T. Rowe Price New Horizons Tr-Z | 8 months ago | 505468 |
| 13. | US Small-Cap Growth II Equity Comp | 8 months ago | 2064248 |
| 14. | T. Rowe Price New Horizons | 7 months ago | 2062908 |
| 15. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 1988563 |
| 16. | Vanguard Health Care Inv | 8 months ago | 1804465 |
| 17. | iShares Russell 2000 ETF | 6 months ago | 1767009 |
| 18. | T. Rowe Price Health Sciences | 7 months ago | 1608102 |
| 19. | Vanguard Small Cap Index | 7 months ago | 1588795 |
| 20. | SPDR® S&P Biotech ETF | 6 months ago | 1259408 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Pictet Asset Manangement SA | 8 months ago | 1166507 |
| 2. | Amvescap Plc. | 8 months ago | 900356 |
| 3. | Polar Capital Holdings PLC | 8 months ago | 877005 |
| 4. | American Century Companies Inc | 8 months ago | 815071 |
| 5. | Vanguard Group Inc | 8 months ago | 6683434 |
| 6. | BlackRock Inc | 11 months ago | 6647297 |
| 7. | T. Rowe Price Associates, Inc. | 8 months ago | 5387267 |
| 8. | FMR Inc | 8 months ago | 4516771 |
| 9. | Wellington Management Company LLP | 8 months ago | 3964610 |
| 10. | State Street Corp | 8 months ago | 2765702 |
| 11. | William Blair Investment Management, LLC | 8 months ago | 1674799 |
| 12. | Geode Capital Management, LLC | 8 months ago | 1480187 |
| 13. | Macquarie Group Ltd | 8 months ago | 1263661 |
| 14. | JPMorgan Chase & Co | 8 months ago | 1222052 |
| 15. | AllianceBernstein L.P. | 8 months ago | 1217705 |
| 16. | Lord, Abbett & Co LLC | 8 months ago | 1178190 |
| 17. | Rock Springs Capital Management LP | 8 months ago | 768776 |
| 18. | T. Rowe Price Investment Management,Inc. | 8 months ago | 748692 |
| 19. | Goldman Sachs Group Inc | 8 months ago | 721632 |
| 20. | Alkeon Capital Management, LLC | 8 months ago | 718928 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...